Health Care

Rani Therapeutics (NASDAQ: RANI) is a volatile biotech with a $168M market cap, negative earnings, and mixed analyst views—buyers see upside, sellers warn of risk.

Ascendis Pharma boosts growth with analyst‑backed buy/overweight ratings, a $120 M share‑repurchase, and strong FY25‑26 revenue outlooks.

PTC Therapeutics, a Nasdaq‑listed biopharma firm, updates compliance status and shows steady stock performance at $77.53, highlighting its focus on small‑molecule drugs for genetic and oncology therapies.

CytoDyn Inc.

Biohaven’s MoDE™ and TRAP™ degraders show early promise in IgA nephropathy and Graves’ disease, offering a new selective protein‑degradation approach that could transform treatment.

Plus Therapeutics’ stock slumps as its REYOBIQ program struggles to excite investors, raising questions about the firm’s future in biotech innovation.

Medical Care Technologies Inc. is pioneering AI‑powered pediatric centers in China, spotlighted by a $50k Jordan jersey test that won $4.5M—yet its tiny cap and volatile shares show investor caution.

Atara Biotherapeutics’ stock surges after a pivotal FDA decision on its viral‑therapy program, sparking investor interest and highlighting the company’s growth potential in biotech.

NeoGenomics forecasts $190 M Q4 2025 revenue and $727 M yearly, while a CFO transition bolsters its precision‑medicine growth momentum.

UnitedHealth Group faces regulatory scrutiny over Medicare reimbursement tactics, amid investor doubts and a looming earnings release that could shape its future.